PE20040131A1 - Formulaciones y formas de dosificacion para la administracion controlada de topiramato - Google Patents

Formulaciones y formas de dosificacion para la administracion controlada de topiramato

Info

Publication number
PE20040131A1
PE20040131A1 PE2003000750A PE2003000750A PE20040131A1 PE 20040131 A1 PE20040131 A1 PE 20040131A1 PE 2003000750 A PE2003000750 A PE 2003000750A PE 2003000750 A PE2003000750 A PE 2003000750A PE 20040131 A1 PE20040131 A1 PE 20040131A1
Authority
PE
Peru
Prior art keywords
topiramate
dosage forms
release
polyoxyl
stearate
Prior art date
Application number
PE2003000750A
Other languages
English (en)
Inventor
Shaoling Li
Winnie To
David Edgren
Robert Skluzacek
Andrew Lam
Atul D Ayer
Shu Li
Patrick S L Wong
Frank Jao
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of PE20040131A1 publication Critical patent/PE20040131A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

QUE COMPRENDE: 1)DE 50% A 60% DE UN AGENTE ACTIVO QUE ES TOPIRAMATO, CUYA DOSIS APROXIMADA ES DE 10 mg A 750 mg; 2)DE 5% A 15% DE UN PORTADOR POLIMERICO ESTRUCTURAL, QUE PUEDE SER OXIDO DE POLIETILENO DE PESO MOLECULAR ENTRE 100 000 Y 200 000; Y, 3)DE 5% A 15% DE UN SURFACTANTE SOLUBILIZANTE, ADAPTADO PARA LIBERAR EL TOPIRAMATO POR UN PERIODO DE TIEMPO PROLONGADO, EL CUAL ES SELECCIONADO DE ESTEARATO DE POLIOXILO 40, ESTEARATO DE POLIOXILO 50, POLOXAMEROS Y COPOLIMEROS DE TRES BLOQUES COMO OXIDO DE ETILENO:OXIDO DE PROPILENO:OXIDO DE ETILENO. SE REFIERE TAMBIEN A FORMAS DE DOSIFICACION DE LIBERACION CONTROLADA TALES COMO SISTEMA DE MATRIZ, SISTEMA OSMOTICO. SE REFIERE TAMBIEN A FORMAS DE DOSIFICACION ORALES QUE COMPRENDEN: a)UN NUCLEO, QUE A SU VEZ INCLUYE: i)TOPIRAMATO; ii)UN POLIMERO ESTRUCTURAL; iii)UN SURFACTANTE SOLUBILIZANTE; b)UNA MEMBRANA SEMIPERMEABLE QUE RODEA POR LO MENOS PARCIALMENTE A (a); Y, c)UN ORIFICIO DE SALIDA A TRAVES DE (b) QUE SE COMUNICA CON (a), A FIN DE PERMITIR LA LIBERACION DE (i)
PE2003000750A 2002-07-29 2003-07-30 Formulaciones y formas de dosificacion para la administracion controlada de topiramato PE20040131A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39999302P 2002-07-29 2002-07-29
US46851903P 2003-05-07 2003-05-07

Publications (1)

Publication Number Publication Date
PE20040131A1 true PE20040131A1 (es) 2004-03-06

Family

ID=31191336

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000750A PE20040131A1 (es) 2002-07-29 2003-07-30 Formulaciones y formas de dosificacion para la administracion controlada de topiramato

Country Status (12)

Country Link
US (1) US20040115262A1 (es)
EP (1) EP1534238A1 (es)
JP (1) JP2005536568A (es)
AR (1) AR040722A1 (es)
AU (1) AU2003256848A1 (es)
CA (1) CA2494233A1 (es)
MX (1) MXPA05001184A (es)
NZ (1) NZ537543A (es)
PE (1) PE20040131A1 (es)
TW (1) TW200410728A (es)
UY (1) UY27908A1 (es)
WO (1) WO2004010970A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
ATE399538T1 (de) * 2003-03-26 2008-07-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050136108A1 (en) * 2003-08-22 2005-06-23 Yam Noymi V. Stepwise delivery of topiramate over prolonged period of time
AU2004268661A1 (en) * 2003-09-02 2005-03-10 Alza Corporation Novel drug compositions and dosage forms of topiramate
NZ546183A (en) * 2003-09-26 2011-04-29 Alza Corp Controlled release formulations exhibiting an ascending rate of release
JP4919801B2 (ja) 2003-09-26 2012-04-18 アルザ・コーポレーシヨン 高い薬剤配合量を提供する薬剤コーティング及びそれを提供する方法
MXPA06005462A (es) * 2003-11-14 2006-12-15 Johnson & Johnson Liberacion controlada de topiramato en formas de dosificacion liquida.
AU2004312083A1 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc. Drug granule coatings that impart smear resistance during mechanical compression
JP2007517063A (ja) * 2003-12-29 2007-06-28 アルザ・コーポレーシヨン トピラメートの新規な薬剤組成物および剤形
MXPA06007509A (es) * 2003-12-29 2007-10-18 Johnson & Johnson Composiciones de farmaco y formas de dosis novedosas.
KR20070013316A (ko) * 2004-05-21 2007-01-30 알자 코포레이션 다중 약물 형태 전달용의 제형
WO2006007323A2 (en) * 2004-06-28 2006-01-19 Alza Corporation Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
CN1988889A (zh) * 2004-07-22 2007-06-27 株式会社太平洋 含托吡酯的缓释制剂及其制备方法
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
JP2008528629A (ja) * 2005-01-27 2008-07-31 アルザ・コーポレーシヨン 高流動性膜を有する経口浸透薬用量形態
IS7748A (is) * 2005-03-17 2006-09-18 Actavis Group Samsetning fyrir töflur sem innihalda topiramate
US20080318910A1 (en) * 2005-10-04 2008-12-25 Mistral Pharma, Inc. Controlled-Release Oral Dosage Form
WO2007044234A1 (en) * 2005-10-07 2007-04-19 Alza Corporation Osmotic dosage form with controlled release and fast release aspects
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
GB2443738A (en) * 2006-11-09 2008-05-14 Proprius Pharmaceuticals Inc A sustained release methotrexate composition and methods of use thereof
ES2555066T3 (es) 2006-11-17 2015-12-28 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
CN102114002B (zh) * 2006-12-04 2016-05-11 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
WO2010100657A2 (en) 2009-03-04 2010-09-10 Fdc Limited A novel oral controlled release dosage forms for water soluble drugs
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
KR20200016889A (ko) 2017-06-02 2020-02-17 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
CN115318353B (zh) * 2022-08-31 2023-09-22 江苏举世检测有限公司 一种应用于管、瓶类卷口容器的恒温水浴锅及使用方法

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US488168A (en) * 1892-12-13 Furnace for burning garbage
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (es) * 1960-11-29
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) * 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3865108A (en) * 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) * 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4207893A (en) * 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4578075A (en) * 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5082655A (en) * 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
US4940465A (en) * 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US5938654A (en) * 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US4957494A (en) * 1987-06-25 1990-09-18 Alza Corporation Multi-layer delivery system
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4824675A (en) * 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4961932A (en) * 1987-10-26 1990-10-09 Alza Corporation Plurality of tiny pills in liquid dosage form
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5262171A (en) * 1991-11-25 1993-11-16 Isp Investments Inc. Pharmaceutical tablet with PVP having enhanced drug dissolution rate
US5413672A (en) * 1992-07-22 1995-05-09 Ngk Insulators, Ltd. Method of etching sendust and method of pattern-etching sendust and chromium films
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
EP1035834B1 (en) * 1997-12-05 2002-04-17 Alza Corporation Osmotic dosage form comprising first and second coats
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
IL142807A0 (en) * 1998-11-02 2002-03-10 Alza Corp Controlled delivery of active agents
DE69930952T2 (de) * 1998-11-02 2006-08-31 Alza Corp., Mountain View Verfahren und Vorrichtung zur kontrollierten Abgabe pharmazeutischer Mittel sowie Dosierungsform hierfür
SI20150A (sl) * 1999-02-19 2000-08-31 Lek, Tovarna Farmacevtskih In Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
MXPA01012187A (es) * 1999-05-28 2002-06-21 Jeffrey Berlant Compuestos y metodos para el tratamiento del trastorno por estres postraumatico.
US6562375B1 (en) * 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US7678387B2 (en) * 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6946243B2 (en) * 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
JP2004514778A (ja) * 2000-11-28 2004-05-20 フォーカル　インコーポレーティッド ポリアルキレングリコール粘度増強性重合製剤
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
EP1377430B1 (de) * 2001-04-10 2005-08-10 Soplar Sa Vorrichtung zur herstellung von hohlkörpern aus kunststoff im extrusionsblasverfahren
US20030021841A1 (en) * 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
JP2005523262A (ja) * 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement

Also Published As

Publication number Publication date
TW200410728A (en) 2004-07-01
AR040722A1 (es) 2005-04-20
JP2005536568A (ja) 2005-12-02
AU2003256848A1 (en) 2004-02-16
UY27908A1 (es) 2003-11-28
MXPA05001184A (es) 2005-09-12
CA2494233A1 (en) 2004-02-05
WO2004010970A1 (en) 2004-02-05
NZ537543A (en) 2007-08-31
US20040115262A1 (en) 2004-06-17
EP1534238A1 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
PE20040131A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
PE20050728A1 (es) Forma de dosificacion a prueba de abuso
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
CY1120462T1 (el) Τοπικες ανθελμινθικες κτηνιατρικες τυποποιησεις
AR051969A1 (es) Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y el manejo de lesiones del sistema nervioso central
AR038575A1 (es) Formulacion oftalmica con nueva composicion de goma
AR065073A2 (es) Una formulacion medicamentosa de sistema de matriz que tiene liberacion controlada de un compuesto activo
PE20040103A1 (es) Metodo y formas de dosificacion para incrementar la solubilidad de composiciones de farmaco para administracion controlada
DE60312523D1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
UY28431A1 (es) Peliculas que se disuelven por via oral
ES2194732T3 (es) Composiciones farmaceuticas orales de liberacion controlada de mesalazina.
PE20010625A1 (es) Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
CO6321222A2 (es) Una forma de dosificacion unitaria que comprende una matriz de pelicula delgada soluble en agua (oblea) que contiene un ingrediente activo
DE60211464D1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
ES2168241T1 (es) Preparacion farmaceutica que contiene tolperisona para administrar por via oral.
AR034493A1 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
AR061351A1 (es) Composicion de carbamato de bencimidazol
DE602004003577D1 (de) Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
BRPI0606119A2 (pt) preparações injetáveis de diclofenaco e seus sais farmaceuticamente aceitáveis
ECSP109871A (es) Soluciones farmacéuticas orales que contienen telbivudina
AR039232A1 (es) Una formulacion farmaceutica que comprende al menos un compuesto seleccionado del grupo formado por hipnoticos no barbituricos y no benzodiacepinicos, y melatonina
PE20050439A1 (es) Forma de dosificacion farmaceutica de liberacion prolongada
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
DOP2006000184A (es) Forma farmacéutica con liberación sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph

Legal Events

Date Code Title Description
FC Refusal